This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Oregon lawmakers are considering changes to the state’s drug transparency law that would prevent pharmaceutical manufacturers from exploiting a potential loophole to avoid reporting price hikes and give state regulators more authority to expect timely information from drug companies.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
An Oregon program that aims to peel back the opaque layers of prescription drug pricing wrapped up its first year this week with a report to the Legislature that underlines
When a long, black bus bearing the logo of drugmaker AbbVie rolls through Washington state next year, it will promote a new effort to eradicate hepatitis C infections.
In the heat of the most ferocious battle over drug prices in years, pharmaceutical companies are showering U.S. senators with campaign cash as sweeping legislation heads toward the floor.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
For people who don’t read much English, following prescription labels can be a guessing game. Those who guess wrong can end up hurt by the medication that was supposed to help them. Even worse, they can end up hospitalized.
Senators got their first opportunity Tuesday to prod drugmakers about the wallet-emptying prices they charge for prescription drugs.
![[image of pills]](https://www.thelundreport.org/sites/default/files/styles/thumbnail/public/article-images/Pills%20by%20The%20Lund%20Report.jpg?itok=sGIwNztC "pills")
Oregon lawmakers have heard more than a dozen bills so far this session on the pharmaceutical industry, many attempting to address skyrocketing costs.
A rare scene of drama erupted in a House health care committee hearing on Tuesday as the chair and a lobbyist for the pharmaceutical industry clashed over a fairly straightforward bill that would require greater transparency on the part of drug manufacturers.
A two-decade surge in opioid overdose deaths has prompted health officials, addiction specialists and the federal government to declare opioid addiction a public health emergency.
